We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Association of alpha-1-adrenergic antagonist use with the risk of gout development in benign prostatic hyperplasia patients: a population-based cohort study.
- Authors
Hsu, Wei-Hung; Lai, Jung-Nien; Lin, Cheng-Li; Loh, Ching-Hui; Huang, Huei-Kai; Huang, Liang-Kai
- Abstract
<bold>Background: </bold>Men are more likely to develop benign prostatic hyperplasia (BPH) and gout as they age. However, the role of alpha-1-adrenergic antagonists, the medication for BPH, in the development of gout is uncertain.<bold>Objective: </bold>To investigate the effect of alpha-1-adrenergic antagonist use on the risk of developing gout in BPH patients.<bold>Methods: </bold>Data of patients with newly diagnosed BPH were retrieved from Taiwan's 2000-2013 National Health Insurance Research Database (total number: 15,390 patients; 7,695 patients in each cohort). Propensity score matching was conducted according to age, comorbidities, medication history for cohorts that received or did not receive alpha-1-adrenergic antagonists. Hazard ratios (HRs) were assessed for gout development using Cox proportional hazards regression models.<bold>Results: </bold>Use of alpha-1-adrenergic antagonists was not associated with gout development in BPH patients (HR = 0.92; 95% confidence interval [CI], 0.78-1.10; P = 0.35). However, after stratification according to the average number of days of alpha-1-adrenergic antagonist use per year, patients with an average of >300 days had a significantly higher risk of gout development than patients who did not receive alpha-1-adrenergic antagonists (adjusted HR = 1.57; 95% CI, 1.25-1.97; P < 0.001). Patients with more days of medication use per year had a higher risk of gout development than those with fewer days of medication use (P < 0.001).<bold>Conclusion: </bold>Patients who received more doses of alpha-1-adrenergic antagonists per year had a higher risk of developing gout. A causal proof of the role of alpha-1-adrenergic antagonists use in gout development should be analysed in future studies designed as double blind randomized controlled trials.
- Subjects
ADRENERGIC alpha blockers; BENIGN prostatic hyperplasia; RESEARCH funding; GOUT; PROPORTIONAL hazards models; LONGITUDINAL method
- Publication
Family Practice, 2022, Vol 39, Issue 3, p426
- ISSN
0263-2136
- Publication type
journal article
- DOI
10.1093/fampra/cmab163